Unknown

Dataset Information

0

Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.


ABSTRACT: Aldose reductase (AR, ALR2), the first enzyme of the polyol pathway, is implicated in the pathophysiology of diabetic complications. Aldose reductase inhibitors (ARIs) thus present a promising therapeutic approach to treat a wide array of diabetic complications. Moreover, a therapeutic potential of ARIs in the treatment of chronic inflammation-related pathologies and several genetic metabolic disorders has been recently indicated. Substituted indoles are an interesting group of compounds with a plethora of biological activities. This article reviews a series of indole-based bifunctional aldose reductase inhibitors/antioxidants (ARIs/AOs) developed during recent years. Experimental results obtained in in vitro, ex vivo, and in vivo models of diabetic complications are presented. Structure-activity relationships with respect to carboxymethyl pharmacophore regioisomerization and core scaffold modification are discussed along with the criteria of 'drug-likeness". Novel promising structures of putative multifunctional ARIs/AOs are designed.

SUBMITTER: Kovacikova L 

PROVIDER: S-EPMC8151378 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8707451 | biostudies-literature
| S-EPMC7992003 | biostudies-literature
| S-EPMC8080350 | biostudies-literature
| S-EPMC7448230 | biostudies-literature
| S-EPMC8335715 | biostudies-literature
| S-EPMC2909072 | biostudies-literature
| S-EPMC7407822 | biostudies-literature
| S-EPMC1190371 | biostudies-literature
| S-EPMC6110315 | biostudies-literature
| S-EPMC3183354 | biostudies-literature